Percutaneous Microwave Ablation for Centrally Located T1b Renal Cell Carcinomas; A Single Centre’s Experience

Saturday, February 1, 2020

7:00 AM – 7:12 AM

Location: Galerie 1/2/3, 2nd Floor

Objective: The objective of this study is to review safety and mid-term efficacy of percutaneous microwave ablation (MWA) for the treatment of Renal Cell Carcinoma (RCC) (centrally located stage T1b lesions).

Methods: Institutional database research identified 11 consecutive patients with a single, biopsy proven renal cell carcinoma T1b lesion which was centrally located. All patients underwent percutaneous microwave ablation using a high power microwave system. Prophylactic ureteric stenting was placed in 5/11 patients. Trans-arterial embolization was additionally performed in 4/10 patients. Contrast-enhanced computed tomography or magnetic resonance imaging was used for post-ablation follow-up. Bipolar microwave ablation with 2 antennas was performed in 2/11 patients. Patient and tumor characteristics, microwave technique, complications, and pattern of recurrence were evaluated.

Results: Mean patient age was 73.8 years (male-female: 6-4). Average lesion size was 5 cm (range 4.2-6.2 cm). Mean follow-up was 14.2 months. Tumor remnant was noted in 1/11 cases which was re-treated. One patient developed metastasis during the follow-up period (soft tissue mass treated with percutaneous ablation). Minor complications including hematomas requiring nothing but observation occurred at 2/11 patients.

Conclusions: Percutaneous microwave ablation of RCC using a high power microwave system is a safe and efficacious technique for the treatment of T1b RCC lesions; trans-arterial embolization as an addition to percutaneous microwave ablation seems to be feasible, efficacious and safe.

Presenting Author(s)

Ornella Moschovaki-Zeiger, MD

Radiology Resident
University General Hospital "ATTIKON"

Disclosure: Disclosure information not submitted.

Author(s)

Dimitrios K. Filippiadis, MD, PhD, EBIR

Assistant Professor
University General Hospital "ATTIKON"

Disclosure: Disclosure information not submitted.
SS

Stavros Spiliopoulos, MD, PhD, EBIR

Assistant Professor
University General Hospital "ATTIKON"

Disclosure: Disclosure information not submitted.
KP

Kwstas Palialexis, MD, PhD

CONSULTANT
University General Hospital "ATTIKON"

Disclosure: Disclosure information not submitted.
Alexis Kelekis, MD, PhD, EBIR

Associate Professor
University General Hospital "ATTIKON"

Disclosure: Disclosure information not submitted.
EB

Elias Brountzos, MD, PhD, EBIR

Disclosure: Disclosure information not submitted.
NK

Nikolaos Kelekis, Ph.D., MD, PhD, EBIR

Professor
University General Hospital "ATTIKON"

Disclosure: Disclosure information not submitted.